Yataro Yoshida

Summary

Affiliation: Ujitakeda Hospital
Country: Japan

Publications

  1. ncbi request reprint Seventh International Symposium on Myelodysplastic Syndromes
    Yataro Yoshida
    Takeda General Hospital, Kyoto, Japan
    Int J Hematol 78:272-5. 2003
  2. ncbi request reprint Co-occurrence of monoclonal gammopathy and myelodysplasia: a retrospective study of fourteen cases
    Yataro Yoshida
    The Center for Hematological Diseases, Takeda General Hospital, Fushimi, Kyoto, 601 1495, Japan
    Int J Hematol 99:721-5. 2014
  3. ncbi request reprint Absent or extremely low neutrophil alkaline phosphatase activity levels in patients with myelodysplastic syndromes
    Yataro Yoshida
    Center for Hematological Diseases, Takeda General Hospital, Japan
    Intern Med 52:479-82. 2013
  4. doi request reprint John Auer and Auer rods; controversies revisited
    Yataro Yoshida
    The Center for Hematological Diseases, Takeda General Hospital, Japan
    Leuk Res 33:614-6. 2009
  5. doi request reprint Historical review. The light and shadow of Paul Kaznelson: his life and contribution to hematology
    Yataro Yoshida
    Center for Hematological Diseases, Takeda General Hospital, 28 1 Ishida Moriminami, Fushimi ku, Kyoto 601 1495, Japan
    Ann Hematol 87:877-9. 2008
  6. ncbi request reprint Evolving new treatment for myelodysplastic syndromes
    Yataro Yoshida
    Takeda General Hospital, Fushimi ku, Kyoto 601 1495, Japan
    Int J Hematol 86:297-300. 2007
  7. ncbi request reprint Peer review system: any other choice?
    Yataro Yoshida
    Takeda General Hospital, Kyoto, Japan
    Int J Hematol 83:191-2. 2006
  8. ncbi request reprint Angioimmunoblastic T-cell lymphoma initially presenting with replacement of bone marrow and peripheral plasmacytosis
    Hisashi Sakai
    Department of Internal Medicine, Takeda General Hospital, Kyoto, Japan
    Intern Med 46:419-24. 2007
  9. ncbi request reprint Immune pancytopenia associated with a leukemic B-cell tumor carrying t(14;18)(q32;q21) translocation
    Chisaki Mizumoto
    Department of Hematology, Takeda General Hospital, Japan
    Intern Med 50:753-6. 2011
  10. doi request reprint The duration of functioning of a subcutaneous implantable port for the treatment of hematological tumors: a single institution-based study
    Hitoshi Ohno
    Department of Hematology, Takeda General Hospital, 28 1 Ishida Moriminami cho, Fushimi ku, Kyoto 601 1495, Japan
    Int J Clin Oncol 15:172-8. 2010

Collaborators

Detail Information

Publications19

  1. ncbi request reprint Seventh International Symposium on Myelodysplastic Syndromes
    Yataro Yoshida
    Takeda General Hospital, Kyoto, Japan
    Int J Hematol 78:272-5. 2003
  2. ncbi request reprint Co-occurrence of monoclonal gammopathy and myelodysplasia: a retrospective study of fourteen cases
    Yataro Yoshida
    The Center for Hematological Diseases, Takeda General Hospital, Fushimi, Kyoto, 601 1495, Japan
    Int J Hematol 99:721-5. 2014
    ..In addition, serum M protein levels remained largely unchanged in 4 cases of MGUS for which serial determinations were performed. These findings indicate that MGUS may not affect the prognosis of MDS. ..
  3. ncbi request reprint Absent or extremely low neutrophil alkaline phosphatase activity levels in patients with myelodysplastic syndromes
    Yataro Yoshida
    Center for Hematological Diseases, Takeda General Hospital, Japan
    Intern Med 52:479-82. 2013
    ..No patients experienced any severe infectious episodes. These results suggest that NAP activity is not central to the neutrophil function...
  4. doi request reprint John Auer and Auer rods; controversies revisited
    Yataro Yoshida
    The Center for Hematological Diseases, Takeda General Hospital, Japan
    Leuk Res 33:614-6. 2009
    ....
  5. doi request reprint Historical review. The light and shadow of Paul Kaznelson: his life and contribution to hematology
    Yataro Yoshida
    Center for Hematological Diseases, Takeda General Hospital, 28 1 Ishida Moriminami, Fushimi ku, Kyoto 601 1495, Japan
    Ann Hematol 87:877-9. 2008
    ..Most of his academic works appeared in 1910s and 1920s, when he used to work in Karl-Ferdinand University in Prague. Trail of his rather tragic postwar life is briefly added...
  6. ncbi request reprint Evolving new treatment for myelodysplastic syndromes
    Yataro Yoshida
    Takeda General Hospital, Fushimi ku, Kyoto 601 1495, Japan
    Int J Hematol 86:297-300. 2007
    ....
  7. ncbi request reprint Peer review system: any other choice?
    Yataro Yoshida
    Takeda General Hospital, Kyoto, Japan
    Int J Hematol 83:191-2. 2006
  8. ncbi request reprint Angioimmunoblastic T-cell lymphoma initially presenting with replacement of bone marrow and peripheral plasmacytosis
    Hisashi Sakai
    Department of Internal Medicine, Takeda General Hospital, Kyoto, Japan
    Intern Med 46:419-24. 2007
    ..Even in the absence of definitive lymph node biopsy, the appearance of the bone marrow and the peripheral blood can lead to the diagnosis of AITL...
  9. ncbi request reprint Immune pancytopenia associated with a leukemic B-cell tumor carrying t(14;18)(q32;q21) translocation
    Chisaki Mizumoto
    Department of Hematology, Takeda General Hospital, Japan
    Intern Med 50:753-6. 2011
    ..The underlying disease was a leukemic B-cell tumor with t(14;18)(q32;q21), and the pancytopenia was mainly caused by autoimmune mechanisms...
  10. doi request reprint The duration of functioning of a subcutaneous implantable port for the treatment of hematological tumors: a single institution-based study
    Hitoshi Ohno
    Department of Hematology, Takeda General Hospital, 28 1 Ishida Moriminami cho, Fushimi ku, Kyoto 601 1495, Japan
    Int J Clin Oncol 15:172-8. 2010
    ..Although subcutaneous implantable ports have been indicated as venous access for chemotherapy, these devices have not been used routinely for hematological tumors...
  11. ncbi request reprint Interferon-alfa treatment of essential thrombocythemia during pregnancy
    Toshiko Iwashita
    Department of Obstetrics and Gynecology, Takeda General Hospital, Kyoto
    Intern Med 45:1161-4. 2006
    ....
  12. ncbi request reprint Polyclonal proliferation of plasma cells associated with marked hypergammaglobulinemia in an elderly patient
    Hitoshi Ohno
    Department of Internal Medicine, Takeda General Hospital, Kyoto, Japan
    Int J Hematol 81:62-5. 2005
    ..Abdominal lymphadenopathy, splenomegaly, and a high level of soluble interleukin 2 receptor may have been reflections of an underlying lymphoproliferative disorder, potentially leading to the polyclonal proliferation of plasma cells...
  13. ncbi request reprint Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome
    Kiyoyuki Ogata
    Division of Hematology, Nippon Medical School, Kyoto, Japan
    Blood 100:3887-96. 2002
    ..Further, CD7 positivity of EBCs was an independent variable for a poor prognosis in MDS. These data represent new, valuable information regarding MDS...
  14. ncbi request reprint A mighty supporter for WHO classification of myelodysplasia
    Yataro Yoshida
    Leuk Res 29:359-60. 2005
  15. ncbi request reprint A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-)CD59(-) blood cells predicts platelet response
    Takayuki Ishikawa
    Department of Hematology and Oncology, Graduate School ofMedicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
    Int J Hematol 86:150-7. 2007
    ..A minority of RA patients who did not possess such predictive variables achieved an isolated erythroid response. In conclusion, CSA may be a therapeutic option for patients with RA who do not have adverse prognostic factors...
  16. ncbi request reprint Association between phenotypic features of blasts and the blast percentage in bone marrow of patients with myelodysplastic syndromes
    Kiyoyuki Ogata
    Division of Hematology, Third Department of Internal Medicine, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo 113 8603, Japan
    Leuk Res 28:1171-5. 2004
    ..The BM blast percentages where the blast immunophenotype changed were 5, 10, 20 and 25%. Blast immunophenotypes have the potential to provide a biological basis for and refine the present MDS classifications...
  17. ncbi request reprint A new look at apoptosis in MDS; an uneasy neighbor
    Yataro Yoshida
    Leuk Res 31:1617-9. 2007
  18. ncbi request reprint Clinical implications of blast immunophenotypes in myelodysplastic syndromes
    Kiyoyuki Ogata
    Division of Hematology, Department of Medicine, Nippon Medical School, Tokyo, Japan
    Leuk Lymphoma 46:1269-74. 2005
    ..Further studies of blast immunophenotypes will deepen our understanding of MDS and hopefully improve the clinical approach to these intractable disorders...
  19. ncbi request reprint [Progress in research on myelodysplastic syndrome in the last 100 years]
    Yataro Yoshida
    Nihon Naika Gakkai Zasshi 91:2095-9. 2002